Cases & Deals

Celularity acquires certain assets from TNK Therapeutics

Clients Celularity Inc.

Jones Day advised Celularity Inc. in connection with its acquisition from TNK Therapeutics of certain intellectual property rights related to TNK's proprietary chimeric antigen receptor ("CAR") constructs and related CARs.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.